This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Repligen (RGEN) Lags Q2 Earnings Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of -7.50% and +3.56%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Repligen (RGEN) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Do Options Traders Know Something About Repligen (RGEN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Repligen (RGEN) stock based on the movements in the options market lately.
Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?
by Zacks Equity Research
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QGEN or RGEN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
QGEN vs. RGEN: Which Stock Is the Better Value Option?
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y
by Zacks Equity Research
RGEN reports better-than-expected first-quarter results. The company increases its total revenue (on a reported basis) guidance for 2025.
Repligen (RGEN) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of 11.43% and 2.85%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Will Repligen (RGEN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Repligen (RGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Earnings Preview: Guardant Health (GH) Q1 Earnings Expected to Decline
by Zacks Equity Research
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen (RGEN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Repligen (RGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GMAB or RGEN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GMAB vs. RGEN: Which Stock Is the Better Value Option?
Repligen (RGEN) Moves 3.7% Higher: Will This Strength Last?
by Zacks Equity Research
Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Ascendis Pharma (ASND) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Repligen's Q4 Earnings Beat Estimates, Revenues In Line
by Zacks Equity Research
RGEN reports decent fourth-quarter results and issues guidance for 2025.
Repligen (RGEN) Beats Q4 Earnings Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of 7.32% and 0.10%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axsome (AXSM) delivered earnings and revenue surprises of 4% and 0.74%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
HRMY vs. RGEN: Which Stock Is the Better Value Option?
by Zacks Equity Research
HRMY vs. RGEN: Which Stock Is the Better Value Option?
Repligen (RGEN) Surges 3.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Repligen (RGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
HRMY or RGEN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HRMY vs. RGEN: Which Stock Is the Better Value Option?
Repligen (RGEN) Up 3.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Company News for Nov 13, 2024
by Zacks Equity Research
Companies In The News Are: MOS, RGEN, SE, FOUR.
Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View
by Zacks Equity Research
RGEN reports better-than-expected third-quarter results. While management lowers its guidance for 2024 total sales, it raises the same for EPS.
Repligen (RGEN) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of 26.47% and 1.19%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 9.68% and 9.38%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Amgen (AMGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.